[Seite 55↓]

Schriftenverzeichnis

(1) Garand R, Robillard N. Immunophenotypic characterization of acute leukemias and chronic lymphoproliferative disorders: practical recommendations and classifications . Hematol Cell Ther 1996; 38(6): 471-486.

(2) Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. Leukemia 1996; 10(5): 877-895.

(3) DiGiuseppe JA, Borowitz MJ. Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin Oncol 1998; 25(1): 6-10.

(4) Borowitz MJ, Bray R, Gascoyne R, Melnick S, Parker JW, Picker L et al. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data analysis and interpretation. Cytometry 1997; 30(5): 236-244.

(5) Huh YO, Andreeff M. Flow cytometry. Clinical and research applications in hematologic malignancies. Hematol Oncol Clin North Am 1994; 8(4): 703-723.

(6) Tefferi A, Bartholmai BJ, Witzig TE, Li CY, Hanson CA, Phyliky RL. Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 1996; 106 (4): 457-461.

(7) Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992; 40(4): 259-263.

(8) Ginaldi L, De MM, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998; 51(5): 364-369.

(9) Witzig TE, Borell TJ, Herath JF, Tefferi A, Li CY, Jenkins RB. Detection of trisomy 12 by FISH in untreated B-chronic lymphocytic leukemia: correlation with stage and CD20 antigen expression intensity. Leuk Lymphoma 1994; 14(5-6): 447-451.

(10) Witzig TE, Li CY, Tefferi A, Katzmann JA. Measurement of the intensity of cell surface antigen expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 1994; 101(3): 312-317.

(11) D'Arena G, Musto P, Cascavilla N, Dell'Olio M, Di RN, Carotenuto M. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol 2000; 64(4 ): 275-281.

(12) Catovsky D, Cherchi M, Brookss D, Bradely J, Zola H. Heterogeneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7. Blood 1981; 58(2): 406-408.

(13) Huh YO, Pugh WC, Kantarjian HM, Stass SA, Cork A, Trujillo JM et al. Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody. Am J Clin Pathol 1994; 101(3): 283-289.

(14) den OG, Schuit HR, Waayer JL, Huibregtsen L, Hijmans W, Jansen J. Chronic B-cell leukemias: relation between morphological and immunological features. Clin Immunol Immunopathol 1985; 35(1): 92-102.


[Seite 56↓]

(15) Matutes E, Oscier D, Garcia-Marco J, Ellis J, Copplestone A, Gillingham R et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 1996; 92(2): 382-388.

(16) Geisler CH, Philip P, Christensen BE, Hou-Jensen K, Pedersen NT, Jensen OM et al. In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. Leuk Res 1997; 21(11-12): 1011-1023.

(17) Geisler CH, Larsen JK, Hansen NE, Hansen MM, Christensen BE, Lund B et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood 1991; 78(7): 1795-1802.

(18) Newman RA, Peterson B, Davey FR, Brabyn C, Collins H, Brunetto VL et al. Phenotypic markers and BCL-1 gene rearrangements in B-cell chronic lymphocytic leukemia: a Cancer and Leukemia Group B study. Blood 1993; 82(4): 1239-1246.

(19) Matutes E, Owusu-Ankomah K, Morilla R, Garcia MJ, Houlihan A, Que TH et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8(10): 1640-1645.

(20) Brooks DA, Beckman IG, Bradley J, McNamara PJ, Thomas ME, Zola H. Human lymphocyte markers defined by antibodies derived from somatic cell hybrids. IV. A monoclonal antibody reacting specifically with a subpopulation of human B lymphocytes. J Immunol 1981; 126(4): 1373-1377.

(21) Zola H, Moore HA, Hohmann A, Hunter IK, Nikoloutsopoulos A, Bradley J. The antigen of mature human B cells detected by the monoclonal antibody FMC7: studies on the nature of the antigen and modulation of its expression. J Immunol 1984; 133(1): 321-326.

(22) Zola H, Neoh SH, Potter A, Melo JV, De OM, Catovsky D. Markers of differentiated B cell leukaemia: CD22 antibodies and FMC7 react with different molecules. Dis Markers 1987; 5(4): 227-235.

(23) Bloem AC, Chand MA, Dollekamp I, Rijkers GT. Functional properties of human B cell subpopulations defined by monoclonal antibodies HB4 and FMC7. J Immunol 1988; 140(3): 768-773.

(24) Rijkers GT, Dollekamp I, Zegers BJ. Evidence that FMC7 is a human B cell differentiation antigen. Immunol Lett 1990; 24(4): 261-264.

(25) Zola H. Human B cells: is FMC7 a marker for relatively mature B cells or does it define a population equivalent to the LyB5-negative mouse B cells?In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, editors. Leukocyte Typing II. New York: Springer, 1986: 141-145.

(26) Zola H, McNamara PJ, Moore HA, Smart IJ , Brooks DA, Beckman IG et al. Maturation of human B lymphocytes--studies with a panel of monoclonal antibodies against membrane antigens. Clin Exp Immunol 1983; 52(3): 655-664.

(27) Ferro LM, Zola H . Modulation of expression of the antigen identified by FMC7 upon human B-lymphocyte activation: evidence for differences between activation in vivo and in vitro. Immunology 1990; 69(3): 373-378.

(28) Hubl W, Iturraspe J, Braylan RC. FMC7 antigen expression on normal and malignant B-cells can be predicted by expression of CD20. Cytometry 1998; 34(2): 71-74.


[Seite 57↓]

(29) D'hautcourt JL, Isaac J. Mean fluorescence intensity of dual stained cells. Cytometry 1999; 38(1): 44-46.

(30) Kehrl JH, Riva A, Wilson GL, Thevenin C . Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. Immunol Today 1994; 15(9): 432-436.

(31) Tedder TF, Klejman G, Schlossman SF, Saito H. Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1). J Immunol 1989; 142(7): 2560-2568.

(32) Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988; 7(3): 711-717.

(33) Stamenkovic I, Seed B. Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein. J Exp Med 1988; 167(6): 1975-1980.

(34) Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125(4): 1678-1685.

(35) Tedder TF, Schlossman SF. Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. J Biol Chem 1988; 263(20): 10009-10015.

(36) Tedder TF, McIntyre G, Schlossman SF. Heterogeneity in the B1 (CD20) cell surface molecule expressed by human B-lymphocytes. Mol Immunol 1988; 25(12): 1321-1330.

(37) Deans JP, Robbins SM, Polyak MJ, Savage JA. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem 1998; 273(1): 344-348.

(38) Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB, Johnson P. Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem 1995; 270(38): 22632-22638.

(39) Deans JP, Schieven GL, Shu GL, Valentine MA, Gilliland LA, Aruffo A et al. Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. J Immunol 1993; 151(9): 4494-4504.

(40) Valentine MA, Meier KE, Rossie S, Clark EA. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem 1989; 264(19): 11282-11287.

(41) Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993; 121(5): 1121-1132.

(42) Kanzaki M, Shibata H, Mogami H, Kojima I. Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J Biol Chem 1995; 270(22): 13099-13104.

(43) Anderson RG. Caveolae: where incoming and outgoing messengers meet . Proc Natl Acad Sci U S A 1993; 90(23): 10909-10913.

(44) Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387(6633): 569-572.


[Seite 58↓]

(45) Parton RG, Simons K. Digging into caveolae. Science 1995; 269(5229): 1398-1399.

(46) Polyak MJ, Tailor SH, Deans JP . Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol 1998; 161(7): 3242-3248.

(47) Whiting PJ. The GABA-A receptor gene family: new targets for therapeutic intervention. Neurochem Int 1999; 34(5): 387-390.

(48) Field KA, Holowka D, Baird B. Compartmentalized activation of the high affinity immunoglobulin E receptor within membrane domains. J Biol Chem 1997; 272(7): 4276-4280.

(49) Mayor S, Rothberg KG, Maxfield FR. Sequestration of GPI-anchored proteins in caveolae triggered by cross-linking. Science 1994; 264(5167): 1948-1951.

(50) Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90(6): 2188-2195.

(51) Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83(2): 435-445.

(52) Dallaire BK, Deardorff J., White C.A., Dowden S., Varns C., Shen D. et al. Antibody therapy with Rituximab for patients with low-grade Non-Hodgkin's Lymphoma. Onkologie 1999; (22): 184-190.

(53) Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91(5): 1644-1652.

(54) Mathas S, Rickers A, Bommert K, Dorken B, Mapara MY. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 2000; 60(24 ): 7170-7176.

(55) Nadler LM, Ritz J, Bates MP, Park EK, Anderson KC, Sallan SE et al. Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia. J Clin Invest 1982; 70(2): 433-442.

(56) Mason DY, Comans-Bitter WM, Cordell JL, Verhoeven MA, van DJ. Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol 1990; 136(6): 1215-1222.

(57) Bourget I, Di BW, Breittmayer JP, Grenier-Brossette N, Plana-Prades M, Bonnefoy JY et al. CD20 monoclonal antibodies stimulate extracellular cleavage of the low affinity receptor for IgE (Fc epsilon RII/CD23) in Epstein-Barr-transformed B cells. J Biol Chem 1994; 269(9): 6927-6930.

(58) Freedman AS, Boyd AW, Bieber FR, Daley J, Rosen K, Horowitz JC et al. Normal cellular counterparts of B cell chronic lymphocytic leukemia. Blood 1987; 70(2): 418-427.

(59) Kilo MN, Dorfman DM. The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma. Am J Clin Pathol 1996; 105(4): 451-457.

(60) Frizzera G, Wu CD, Inghirami G. The usefulness of immunophenotypic and genotypic studies in the diagnosis and classification of hematopoietic and lymphoid neoplasms. An update. Am J Clin Pathol 1999; 111(1 Suppl 1):S13-S39.


[Seite 59↓]

(61) Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84(8): 2457-2466.

(62) Huhn D, von SC, Wilhelm M, Ho AD, Hallek M, Kuse R et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98(5): 1326-1331.

(63) Tedder TF, Streuli M, Schlossman SF, Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes . Proc Natl Acad Sci U S A 1988; 85(1): 208-212.

(64) Thevenin C, Lucas BP, Kozlow EJ, Kehrl JH. Cell type- and stage-specific expression of the CD20/B1 antigen correlates with the activity of a diverged octamer DNA motif present in its promoter. J Biol Chem 1993; 268(8): 5949-5956.

(65) Himmelmann A, Riva A, Wilson GL, Lucas BP, Thevenin C, Kehrl JH. PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. Blood 1997; 90(10): 3984-3995.

(66) Adra CN, Lelias JM, Kobayashi H, Kaghad M, Morrison P, Rowley JD et al. Cloning of the cDNA for a hematopoietic cell-specific protein related to CD20 and the beta subunit of the high-affinity IgE receptor: evidence for a family of proteins with four membrane-spanning regions. Proc Natl Acad Sci U S A 1994; 91(21): 10178-10182.

(67) Liang Y, Buckley TR, Tu L, Langdon SD, Tedder TF. Structural organization of the human MS4A gene cluster on Chromosome 11q12. Immunogenetics 2001; 53(5): 357-368.

(68) Blank U, Ra C, Miller L, White K, Metzger H, Kinet JP. Complete structure and expression in transfected cells of high affinity IgE receptor. Nature 1989; 337(6203): 187-189.

(69) Liang Y, Tedder TF. Identification of a CD20-, FcepsilonRIbeta-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse. Genomics 2001; 72(2): 119-127.

(70) Di VF, Chiozzi P, Ferrari D, Falzoni S, Sanz JM, Morelli A et al. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 2001; 97(3): 587-600.

(71) Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15(9): 450-454.

(72) Yokose N, Ogata K, Sugisaki Y, Mori S, Yamada T, An E et al. CD20-positive T cell leukemia/lymphoma: case report and review of the literature. Ann Hematol 2001; 80(6): 372-375.

(73) Algino KM, Thomason RW, King DE, Montiel MM, Craig FE. CD20 (pan-B cell antigen) expression on bone marrow-derived T cells. Am J Clin Pathol 1996; 106(1): 78-81.

(74) Hultin LE, Hausner MA, Hultin PM, Giorgi JV. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 1993; 14(2): 196-204.


[Seite 60↓]

(75) Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000; 165(11): 6635-6643.

(76) Leveille C, AL-Daccak R, Mourad W. CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. Eur J Immunol 1999; 29(1): 65-74.

(77) Finn WG, Thangavelu M, Yelavarthi KK, Goolsby CL, Tallman MS, Traynor A et al. Karyotype correlates with peripheral blood morphology and immunophenotype in chronic lymphocytic leukemia. Am J Clin Pathol 1996; 105(4): 458-467.

(78) Scott CS, Stark AN, Head C, Roberts BE. Diagnostic features and survival in typical and prolymphocytoid variants of chronic lymphocytic leukemia. Hematol Oncol 1989; 7(2): 175-179.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
22.07.2004